Tuberculosis : progress and advances in development of new drugs, treatment regimens, and host-directed therapies
Copyright © 2018 Elsevier Ltd. All rights reserved..
Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant (MDR), with less than 50% survival after receiving recommended treatment regimens. Concerted efforts of stakeholders, advocates, and researchers are advancing further development of shorter course, more effective, safer, and better tolerated treatment regimens. We review the developmental pipeline and landscape of new and repurposed tuberculosis drugs, treatment regimens, and host-directed therapies (HDTs) for drug-sensitive and drug-resistant tuberculosis. 14 candidate drugs for drug-susceptible, drug-resistant, and latent tuberculosis are in clinical stages of drug development; nine are novel in phase 1 and 2 trials, and three new drugs are in advanced stages of development for MDR tuberculosis. Specific updates are provided on clinical trials of bedaquiline, delamanid, pretomanid, and other licensed or repurposed drugs that are undergoing investigation, including trials aimed at shortening duration of tuberculosis treatment, improving treatment outcomes and patient adherence, and reducing toxic effects. Ongoing clinical trials for shortening tuberculosis treatment duration, improving treatment outcomes in MDR tuberculosis, and preventing disease in people with latent tuberculosis infection are reviewed. A range of HDTs and immune-based treatments are under investigation as adjunctive therapy for shortening duration of therapy, preventing permanent lung injury, and improving treatment outcomes of MDR tuberculosis. We discuss the HDT development pipeline, ongoing clinical trials, and translational research efforts for adjunct tuberculosis treatment.
| Errataetall: |
ErratumIn: Lancet Infect Dis. 2018 Apr 27;:. - PMID 29709349 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
The Lancet. Infectious diseases - 18(2018), 7 vom: 15. Juli, Seite e183-e198 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tiberi, Simon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antitubercular Agents |
|---|
| Anmerkungen: |
Date Completed 09.04.2019 Date Revised 09.04.2019 published: Print-Electronic ErratumIn: Lancet Infect Dis. 2018 Apr 27;:. - PMID 29709349 Citation Status MEDLINE |
|---|
| doi: |
10.1016/S1473-3099(18)30110-5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM282360905 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM282360905 | ||
| 003 | DE-627 | ||
| 005 | 20231225033743.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(18)30110-5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0941.xml |
| 035 | |a (DE-627)NLM282360905 | ||
| 035 | |a (NLM)29580819 | ||
| 035 | |a (PII)S1473-3099(18)30110-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tiberi, Simon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tuberculosis |b progress and advances in development of new drugs, treatment regimens, and host-directed therapies |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.04.2019 | ||
| 500 | |a Date Revised 09.04.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Lancet Infect Dis. 2018 Apr 27;:. - PMID 29709349 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Tuberculosis remains the world's leading cause of death from an infectious disease, responsible for an estimated 1 674 000 deaths annually. WHO estimated 600 000 cases of rifampicin-resistant tuberculosis in 2016-of which 490 000 were multidrug resistant (MDR), with less than 50% survival after receiving recommended treatment regimens. Concerted efforts of stakeholders, advocates, and researchers are advancing further development of shorter course, more effective, safer, and better tolerated treatment regimens. We review the developmental pipeline and landscape of new and repurposed tuberculosis drugs, treatment regimens, and host-directed therapies (HDTs) for drug-sensitive and drug-resistant tuberculosis. 14 candidate drugs for drug-susceptible, drug-resistant, and latent tuberculosis are in clinical stages of drug development; nine are novel in phase 1 and 2 trials, and three new drugs are in advanced stages of development for MDR tuberculosis. Specific updates are provided on clinical trials of bedaquiline, delamanid, pretomanid, and other licensed or repurposed drugs that are undergoing investigation, including trials aimed at shortening duration of tuberculosis treatment, improving treatment outcomes and patient adherence, and reducing toxic effects. Ongoing clinical trials for shortening tuberculosis treatment duration, improving treatment outcomes in MDR tuberculosis, and preventing disease in people with latent tuberculosis infection are reviewed. A range of HDTs and immune-based treatments are under investigation as adjunctive therapy for shortening duration of therapy, preventing permanent lung injury, and improving treatment outcomes of MDR tuberculosis. We discuss the HDT development pipeline, ongoing clinical trials, and translational research efforts for adjunct tuberculosis treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antitubercular Agents |2 NLM | |
| 700 | 1 | |a du Plessis, Nelita |e verfasserin |4 aut | |
| 700 | 1 | |a Walzl, Gerhard |e verfasserin |4 aut | |
| 700 | 1 | |a Vjecha, Michael J |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Ntoumi, Francine |e verfasserin |4 aut | |
| 700 | 1 | |a Mfinanga, Sayoki |e verfasserin |4 aut | |
| 700 | 1 | |a Kapata, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Mwaba, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a McHugh, Timothy D |e verfasserin |4 aut | |
| 700 | 1 | |a Ippolito, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Migliori, Giovanni Battista |e verfasserin |4 aut | |
| 700 | 1 | |a Maeurer, Markus J |e verfasserin |4 aut | |
| 700 | 1 | |a Zumla, Alimuddin |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Lancet. Infectious diseases |d 2001 |g 18(2018), 7 vom: 15. Juli, Seite e183-e198 |w (DE-627)NLM117564362 |x 1474-4457 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:7 |g day:15 |g month:07 |g pages:e183-e198 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/S1473-3099(18)30110-5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 7 |b 15 |c 07 |h e183-e198 | ||